ACOPY logo

The a2 Milk Company Limited (ACOPY)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

ACOPY steht fuer The a2 Milk Company Limited, ein Consumer Defensive-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 54/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.

Zuletzt analysiert: 16. März 2026
54/100 KI-Bewertung

The a2 Milk Company Limited (ACOPY) Konsumgueeter-Geschaeftsueberblick

CEODavid L. Bortolussi
Mitarbeiter488
HauptsitzAuckland, NZ
IPO-Jahr2019

The a2 Milk Company Limited specializes in A2 protein milk and infant formula, differentiating itself through a focus on digestive wellness and operating across Australia, New Zealand, China, and the United States, positioning it within the consumer defensive sector with a focus on health-conscious consumers.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 16. März 2026

Investmentthese

The a2 Milk Company presents a unique investment proposition centered on its specialized A2 protein milk and infant formula products. With a current P/E ratio of 22.89 and a profit margin of 10.9%, the company demonstrates solid profitability. Key growth catalysts include further expansion in the Chinese market and increased penetration in the U.S. market. The company's strong brand recognition and focus on digestive wellness provide a competitive edge. Potential risks include regulatory changes in the infant formula market and increasing competition from established dairy players. Investors should monitor the company's ability to maintain its premium pricing and manage supply chain complexities. The dividend yield of 1.77% offers a modest return, adding to the investment case.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Market capitalization of $4.90 billion reflects investor confidence in the company's growth prospects.
  • Gross margin of 46.8% indicates strong pricing power and efficient cost management.
  • Profit margin of 10.9% demonstrates the company's ability to convert revenue into profit.
  • Beta of 0.46 suggests lower volatility compared to the overall market.
  • Dividend yield of 1.77% provides a steady income stream for investors.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Strong brand recognition and reputation for quality.
  • Focus on a niche market with specific consumer needs.
  • Established distribution network in key markets.
  • Proprietary knowledge and technology related to A2 protein milk.

Schwaechen

  • Reliance on a single product category (A2 protein milk).
  • Limited geographic diversification.
  • Vulnerability to changes in consumer preferences.
  • Potential supply chain disruptions.

Katalysatoren

  • Ongoing: Continued expansion in the Chinese market, driven by high demand for premium infant formula.
  • Ongoing: Increased penetration in the U.S. market, targeting health-conscious consumers.
  • Upcoming: Potential new product launches, such as A2 protein-based dairy alternatives, in Q3 2026.
  • Ongoing: Strategic partnerships with retailers and distributors to expand reach.
  • Ongoing: Growing consumer awareness of the benefits of A2 protein milk.

Risiken

  • Potential: Increasing competition from established dairy players in the A2 protein milk market.
  • Potential: Regulatory changes in the infant formula market, particularly in China.
  • Potential: Fluctuations in raw material prices, such as milk and packaging materials.
  • Potential: Changes in consumer preferences and demand for A2 protein milk.
  • Ongoing: Currency risk associated with international operations.

Wachstumschancen

  • Expansion in China: The Chinese market represents a significant growth opportunity for The a2 Milk Company, driven by high demand for premium infant formula and increasing disposable incomes. The company can leverage its brand recognition and distribution network to further penetrate this market. The Chinese infant formula market is estimated to be worth over $25 billion, offering substantial revenue potential. Timeline: Ongoing.
  • Increased Penetration in the U.S. Market: The U.S. market offers considerable growth potential for a2 Milk, particularly among health-conscious consumers and those seeking alternatives to traditional dairy products. The company can expand its distribution channels and increase marketing efforts to raise brand awareness. The U.S. dairy alternatives market is projected to reach $45 billion by 2027. Timeline: Ongoing.
  • Product Innovation: The a2 Milk Company can drive growth through product innovation, such as developing new A2 protein-based products and expanding its product line to include other dairy-related items. This can attract new customers and increase sales among existing customers. The market for innovative dairy products is growing rapidly, driven by changing consumer preferences. Timeline: Ongoing.
  • Strategic Partnerships: Forming strategic partnerships with retailers and distributors can help The a2 Milk Company expand its reach and increase sales. Collaborating with key players in the dairy and infant formula industries can provide access to new markets and distribution channels. Strategic partnerships can accelerate growth and reduce costs. Timeline: Ongoing.
  • Geographic Expansion: The a2 Milk Company can explore opportunities to expand into new geographic markets, such as Southeast Asia and Europe, where there is growing demand for premium dairy products. Entering new markets can diversify revenue streams and reduce reliance on existing markets. The global dairy market is expected to grow at a CAGR of 4% over the next five years. Timeline: Ongoing.

Chancen

  • Expansion in China and other Asian markets.
  • Increased penetration in the U.S. market.
  • Product innovation and development of new A2 protein-based products.
  • Strategic partnerships with retailers and distributors.

Risiken

  • Increasing competition from established dairy players.
  • Regulatory changes in the infant formula market.
  • Fluctuations in raw material prices.
  • Changes in consumer perceptions of A2 protein milk.

Wettbewerbsvorteile

  • Brand recognition and reputation for quality.
  • Proprietary knowledge and technology related to A2 protein milk.
  • Established distribution network in key markets.
  • Focus on a niche market with specific consumer needs.

Ueber ACOPY

The a2 Milk Company Limited was founded in 2000 in Auckland, New Zealand, with the aim of commercializing milk products containing only the A2 type of beta-casein protein. The company's core innovation lies in identifying and segregating cows that naturally produce milk without the A1 beta-casein protein, which some studies suggest can cause digestive discomfort in certain individuals. This led to the development of the a2 Milk brand, which is now the company's flagship product. Over the years, a2 Milk has expanded its product line to include infant formula under the a2 Platinum brand, catering to the growing demand for premium infant nutrition. The company has strategically expanded its geographic footprint, establishing a significant presence in Australia and New Zealand, and aggressively targeting the Chinese market, where demand for high-quality infant formula is substantial. It also operates in the United States, focusing on health-conscious consumers. The a2 Milk Company differentiates itself through its focus on A2 protein milk and related products, positioning itself as a premium brand in the consumer defensive sector.

Was das Unternehmen tut

  • Sells fresh milk under the a2 Milk brand.
  • Offers infant formula under the a2 Platinum brand.
  • Focuses on products containing only the A2 type of beta-casein protein.
  • Markets its products in Australia, New Zealand, China, and the United States.
  • Targets health-conscious consumers and those seeking digestive wellness.
  • Differentiates itself through its focus on A2 protein milk.

Geschaeftsmodell

  • Produces and sells A2 protein type branded milk.
  • Generates revenue from the sale of fresh milk and infant formula.
  • Focuses on premium pricing and brand differentiation.
  • Utilizes a distribution network to reach consumers in key markets.

Branchenkontext

The a2 Milk Company operates within the agricultural farm products industry, a segment of the broader consumer defensive sector. The industry is characterized by stable demand, as food and beverage products are essential consumer needs. The global dairy market is highly competitive, with major players such as BICEY (Danone), CHFLF (Nestle), COCSF (Fonterra), CUYTY (Unilever), and GLAPY (Lactalis) vying for market share. The a2 Milk Company differentiates itself by focusing on A2 protein milk, catering to consumers seeking digestive wellness. The market for infant formula is particularly lucrative, driven by increasing birth rates in developing countries and growing awareness of premium nutrition.

Wichtige Kunden

  • Health-conscious consumers seeking digestive wellness.
  • Parents looking for premium infant formula.
  • Retail consumers in Australia, New Zealand, China, and the United States.
  • Consumers seeking alternatives to traditional dairy products.
KI-Zuversicht: 71% Aktualisiert: 16. März 2026

Finanzdaten

Chart & Info

The a2 Milk Company Limited (ACOPY) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Keine aktuellen Nachrichten fuer ACOPY verfuegbar.

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ACOPY.

Kursziele

Wall-Street-Kurszielanalyse fuer ACOPY.

MoonshotScore

54/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von ACOPY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Fuehrung: David L. Bortolussi

CEO

David L. Bortolussi serves as the CEO of The a2 Milk Company Limited, overseeing the company's global operations and strategic direction. His career spans various leadership roles in the consumer goods industry, bringing extensive experience in brand management, marketing, and international expansion. Before joining The a2 Milk Company, Bortolussi held senior positions at prominent multinational corporations, where he led successful product launches and market development initiatives. He is known for his strategic vision and ability to drive growth in competitive markets.

Erfolgsbilanz: Under David L. Bortolussi's leadership, The a2 Milk Company has continued to expand its presence in key markets such as China and the United States. He has focused on strengthening the company's brand recognition and improving its supply chain efficiency. Bortolussi has also overseen the development of new product offerings and the implementation of innovative marketing strategies. His tenure has been marked by a commitment to sustainable growth and shareholder value.

The a2 Milk Company Limited ADR-Informationen Nicht gesponsert

An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For ACOPY, each ADR represents a certain number of shares of The a2 Milk Company Limited traded on its home market. This allows U.S. investors to easily invest in ACOPY without dealing with foreign exchanges.

  • Heimatmarkt-Ticker: New Zealand Stock Exchange (NZX), Auckland, New Zealand
  • ADR-Stufe: 1
  • ADR-Verhaeltnis: 1:1
  • Heimatmarkt-Ticker: ACOP
Waehrungsrisiko: As an ADR, ACOPY is subject to currency risk. The value of the ADR can be affected by fluctuations in the exchange rate between the U.S. dollar and the New Zealand dollar. If the New Zealand dollar weakens against the U.S. dollar, the value of the ADR may decrease, and vice versa.
Steuerliche Auswirkungen: Dividends paid on ACOPY ADRs may be subject to foreign dividend withholding tax in New Zealand. The standard withholding tax rate is typically around 15-30%, but this may be reduced or eliminated depending on the tax treaty between the U.S. and New Zealand. Investors should consult with a tax advisor to determine the specific tax implications.
Handelszeiten: The New Zealand Stock Exchange (NZX) operates during different hours than U.S. stock exchanges. The NZX is typically open from 10:00 AM to 4:45 PM New Zealand time, which translates to 5:00 PM to 11:45 PM Eastern Time the previous day. This means that there is limited overlap between the trading hours of the home market and the U.S. market, which can affect the liquidity and trading volume of the ADR.

ACOPY OTC-Marktinformationen

The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and transparency.

  • OTC-Stufe: OTC Other
  • Offenlegungsstatus: Unknown
Liquiditaet: Liquidity for ACOPY on the OTC market is likely to be limited, with potentially low trading volume and a wide bid-ask spread. This can make it difficult to buy or sell shares quickly and at a favorable price. Investors should be aware of the potential for price volatility and illiquidity when trading ACOPY on the OTC market.
OTC-Risikofaktoren:
  • Limited financial disclosure and transparency.
  • Potential for price manipulation and fraud.
  • Higher risk of illiquidity and price volatility.
  • Lack of regulatory oversight and investor protection.
  • Uncertainty regarding the company's financial condition and future prospects.
Sorgfaltspruefung-Checkliste:
  • Verify the company's registration and legal status.
  • Review the company's financial statements, if available.
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's growth prospects and potential risks.
  • Consult with a financial advisor and conduct thorough research.
  • Understand the risks associated with investing in OTC stocks.
Legitimitaetssignale:
  • Established presence in key markets (Australia, New Zealand, China, United States).
  • Focus on a niche market with specific consumer needs (A2 protein milk).
  • Brand recognition and reputation for quality.
  • Continued operations since incorporation in 2000.
  • Presence of a CEO and management team.

Haeufige Fragen zu ACOPY

What are the key factors to evaluate for ACOPY?

The a2 Milk Company Limited (ACOPY) currently holds an AI score of 54/100, indicating moderate score. Key strength: Strong brand recognition and reputation for quality.. Primary risk to monitor: Potential: Increasing competition from established dairy players in the A2 protein milk market.. This is not financial advice.

How frequently does ACOPY data refresh on this page?

ACOPY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven ACOPY's recent stock price performance?

Recent price movement in The a2 Milk Company Limited (ACOPY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong brand recognition and reputation for quality.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider ACOPY overvalued or undervalued right now?

Determining whether The a2 Milk Company Limited (ACOPY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying ACOPY?

Before investing in The a2 Milk Company Limited (ACOPY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding ACOPY to a portfolio?

Potential reasons to consider The a2 Milk Company Limited (ACOPY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Strong brand recognition and reputation for quality.. Additionally: Focus on a niche market with specific consumer needs.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of ACOPY?

Yes, most major brokerages offer fractional shares of The a2 Milk Company Limited (ACOPY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track ACOPY's earnings and financial reports?

The a2 Milk Company Limited (ACOPY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ACOPY earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Limited analyst coverage due to OTC listing.
  • Disclosure status on OTC markets is unknown.
Datenquellen

Popular Stocks